Every material Form 8-K Upstream Bio, Inc. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Upstream Bio announced its pivotal Phase 3 development plans for verekitug, a drug candidate in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company remains on track to start both trials in the first quarter of 2027 and says it could seek approval and launch as early as 2030 if results are supportive. The filing contains no financial results, so the update is a development milestone rather than a change in reported financial performance.
Phase 3 plan: one placebo-controlled study in each indication, about 1,500 patients total, testing 400mg every 12 weeks
Asthma primary endpoint: annualized asthma exacerbation rates over 48 weeks
CRSwNP co-primary endpoints: change from baseline in nasal polyp score and nasal congestion score at 48 weeks
Trials expected to start in Q1 2027; potential U.S. launch as early as 2030 if Phase 3 results are supportive
Upstream Bio reported second-quarter 2026 results with a net loss of $39.7 million, compared with $40.0 million a year earlier, and collaboration revenue of $773,000, down from $937,000. The company said it remains on track to start Phase 3 trials of verekitug in severe asthma and CRSwNP in the first quarter of 2027, and that its cash runway extends through 2027, which matters to shareholders as the company funds its clinical program.
Net loss of $39.7 million for Q2 2026 versus $40.0 million in Q2 2025
Research and development expenses of $36.1 million, down from $37.9 million
Cash, cash equivalents and short-term investments of $261.3 million as of June 30, 2026, expected to fund operations through 2027
Phase 3 trials in severe asthma and CRSwNP targeted to begin in Q1 2027; COPD Phase 2 data expected in second half of 2027
Upstream Bio reported a first-quarter 2026 net loss of $40.6 million, up from $27.3 million a year earlier, as research and development spending rose to $36.6 million. The company also said it will cap enrollment in its Phase 2 COPD trial and now expects data in the second half of 2027, while cash and short-term investments of $294.6 million are expected to fund operations through 2027.
Net loss was $40.6 million for the quarter ended March 31, 2026, compared with $27.3 million a year earlier.
Research and development expenses rose to $36.6 million from $25.8 million, driven by verekitug clinical and manufacturing costs.
Collaboration revenue was $1.0 million, compared with $0.6 million a year earlier.
Enrollment in the Phase 2 VENTURE COPD trial will be capped, with data now expected in the second half of 2027; Phase 3 starts in severe asthma and CRSwNP are expected in Q1 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Upstream Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →